By 2050, the number of people in China aged 65 or older is expected to reach 330 million. China’s rapidly aging population will create significant pressure on economic growth and pose substantial societal and healthcare challenges, including healthcare expenditures and difficulties in managing patient access, quality of health care, and governmental budgets. This remarkable demographic shift will also create market opportunities as well as the need for innovative healthcare paradigms.

BIO is honored to host China’s leading government think tank to showcase key government policies aimed to address the healthcare and market needs of China’s aging population. In addition, join our distinguished panel of government officials and industry leaders to discuss how the innovative biopharmaceutical industry can provide solutions and help address China’s looming demographic crisis.

Healthy Aging: China’s Challenges and Options
Presentation by Wenmeng Feng
Research Fellow, Development Research Center of the State Council of the People’s Republic of China (DRC)

Expert Discussion

• Lie-Jun Wang, Deputy Director General, Division of Social Development Research, DRC

• Paul A. Neureiter, Executive Director for International Government Affairs, Amgen

• Ding Xu, Vice President, Head of Communications and Government Affairs, Emerging Markets, GSK

• Yan Hou, Director General Emeritus, Planning and Information Division, China National Health and Family Planning Commission

Moderator: Monica He, Director for International Affairs, BIO

Ability Level: All

Session ID: 563084